Erik de Clercq
Direktor/Vorstandsmitglied bei FermaVir Pharmaceuticals LLC
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| John Brancaccio | M | 76 |
FermaVir Pharmaceuticals LLC
 FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 19 Jahre |
| Richard Whitley | M | 78 |
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 19 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Gabriele Cerrone | M | 52 |
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 3 Jahre |
| Geoffrey W. Henson | M | 76 |
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 2 Jahre |
| Christopher McGuigan | M | 65 |
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 2 Jahre |
| Frederick Larcombe | M | 67 |
FermaVir Pharmaceuticals LLC
FermaVir Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FermaVir Pharmaceuticals, Inc. develops pharmaceutical products. The company manufactures compounds for the treatment of varicella zoster virus and chickenpox and human cytomegalovirus. It conducts preclinical trials on FV-100, a prodrug of a compound CF-1743, for the treatment of shingles. FermaVir Pharmaceuticals was founded in December, 2004 and is headquartered in New York City, NY. | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 6 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Erik de Clercq
- Persönliches Netzwerk
